Analysis for the engraftment* of HSC-derived cells in NSG mice
| . | Cells injected . | |||
|---|---|---|---|---|
| HSC† . | HSC + proT2‡ . | |||
| Weeks after injection . | Percent in BM§ . | Percent in thymus§ . | Percent in BM§ . | Percent in thymus§ . |
| 3-6 | 89 (8/9) | 11 (1/9) | 100 (8/8) | 63 (5/8)|| |
| 9-12 | 100 (13/13) | 31 (4/13) | 100 (13/13) | 70 (9/13)|| |
| . | Cells injected . | |||
|---|---|---|---|---|
| HSC† . | HSC + proT2‡ . | |||
| Weeks after injection . | Percent in BM§ . | Percent in thymus§ . | Percent in BM§ . | Percent in thymus§ . |
| 3-6 | 89 (8/9) | 11 (1/9) | 100 (8/8) | 63 (5/8)|| |
| 9-12 | 100 (13/13) | 31 (4/13) | 100 (13/13) | 70 (9/13)|| |
Engraftment of HSC-derived cells defined by the presence of >1% human CD45+ HLA-A2+ in the thymus or BM of host NSG mice.
HSC were sorted from UCB as Lin− CD34+ CD38−/low cells, 2 × 104 cells injected/mouse.
The proT2-cells were generated from HSC/OP9-DL1 cultures after 10-12 days, and they were sorted as CD34+ CD7++ CD5+ cells, 2 × 105 cells injected/mouse.
Numbers in parentheses represent the number of mice engrafted of the total number injected.
P < .05 for the presence of HLA-A2+ cells in the thymus of HSC+ proT2-injected mice in comparison with HSC alone.